GILDGILD
US • —
$126.34
P/E
17.19
PEG
0.31
FCF Yield
—
Rev Growth YoY
+3.5% YoY
Gross Margin
79.3%
Health Score
7/10
D/E Ratio
1.10
Confidence
MEDIUM
Business Snapshot
Gilead Sciences operates as a biopharmaceutical company, primarily focused on developing and commercializing therapies in areas such as virology (HIV and hepatitis), oncology, and inflammation. It holds a dominant competitive position in the HIV treatment market, supported by a portfolio of long-acting and single-tablet regimens that generate the majority of its revenue. The company is a large-cap player with a significant commercial footprint, though its exact market capitalisation and trailing twelve-month revenue figures are not available in this data set. A defining characteristic is the company's strong pricing power and patent-protected portfolio, which provides a durable revenue moat while also exposing it to patent cliff risks as key products face generic competition.
Financial Health
Gross margin stands at a robust 79.3%, while net margin is a healthy 31.0%, indicating strong pricing power and operational efficiency. The balance sheet appears well-managed with a debt-to-equity ratio of 1.1x and a current ratio of 1.55x, suggesting a healthy liquidity position and manageable leverage...
Risk Assessment
- INSIDER SELLING — Insiders have executed 4 sells versus 0 buys over the last 90 days, signalling a cautious internal view on near-term prospects.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- EARNINGS QUALITY — While earnings growth is high at 55.5%, it is significantly disconnected from modest 3.5% revenue growth, raising questions about sustainability and whether it is driven by one-time factors.
- DATA GAPS — A core fundamental metric (free cash flow) was missing, limiting the ability to fully assess cash generation and intrinsic valuation....
Gross margin stands at a robust 79.3%, while net margin is a healthy 31.0%, indicating strong pricing power and operational efficiency. The balance sheet appears well-managed with a debt-to-equity ratio of 1.1x and a current ratio of 1.55x, suggesting a healthy liquidity position and manageable leverage. Free cash flow data is unavailable in this analysis, preventing a direct assessment of the company's cash generation capacity or FCF yield. Overall, Gilead demonstrates solid profitability and a manageable debt load, which supports ongoing reinvestment in its pipeline and the potential for sustained shareholder returns through dividends and buybacks.
- INSIDER SELLING — Insiders have executed 4 sells versus 0 buys over the last 90 days, signalling a cautious internal view on near-term prospects. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - EARNINGS QUALITY — While earnings growth is high at 55.5%, it is significantly disconnected from modest 3.5% revenue growth, raising questions about sustainability and whether it is driven by one-time factors. - DATA GAPS — A core fundamental metric (free cash flow) was missing, limiting the ability to fully assess cash generation and intrinsic valuation.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives